British scientists bypass drug giants to sell potential coronavirus vaccine
A team of British scientists developing a coronavirus vaccine has set up a special company to distribute it if they are successful, rather than partnering with a big pharmaceutical company, to ensure access for the world's poorest.
The scientists from London's Imperial College hope to bring a low-cost vaccine to the world early next year via a social enterprise — a company that seeks to do good as well as making a profit.
"Right now we think the focus should be on how to solve the problem rather than how to make money out of it," said Simon Hepworth, director of enterprise at Imperial.
"Social enterprise fits with our mission - applying scientific discoveries for the benefit of society," he said.
There is intense pressure to develop a vaccine for the new coronavirus, which has already cost hundreds of thousands of lives and millions of jobs globally, with about 100 candidates in development.
Some fear people in wealthier countries, where many of the vaccines and treatments are being developed, will receive them ahead of those in poorer countries.
One of the forerunning vaccinations undergoing clinical trials by a team at Oxford University is already being manufactured by British drugmaker AstraZeneca, which has said it will distribute the vaccine at no profit during the pandemic.
Rather than partnering with one company, Imperial is looking to team up with multiple manufacturers, which could include major pharmaceutical companies.
The social enterprise, called VacEquity Global Health (VGH), is backed by Imperial College and Hong Kong-based Morningside Ventures, which invests in companies that use innovative science for public good.
Imperial College is waiving royalties and will charge a "modest" amount for the vaccination, which was developed with funding from the British government and philanthropic organisations, to cover its costs.
Human clinical trials for the vaccine begin next week, with the aim of distributing the vaccine next year, if it proves safe and effective.
Comments
Press Office
Announcements
What's On
Subscribe to improve your user experience...
Option 1 (equivalent of R125 a month):
Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format
Option 2 (equivalent of R375 a month):
All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors
including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.
Already a subscriber?
Forgotten your password?
Receive weekly copy of Creamer Media's Engineering News & Mining Weekly magazine (print copy for those in South Africa and e-magazine for those outside of South Africa)
➕
Recieve daily email newsletters
➕
Access to full search results
➕
Access archive of magazine back copies
➕
Access to Projects in Progress
➕
Access to ONE Research Report of your choice in PDF format
RESEARCH CHANNEL AFRICA
R4500 (equivalent of R375 a month)
SUBSCRIBEAll benefits from Option 1
➕
Access to Creamer Media's Research Channel Africa for ALL Research Reports on various industrial and mining sectors, in PDF format, including on:
Electricity
➕
Water
➕
Energy Transition
➕
Hydrogen
➕
Roads, Rail and Ports
➕
Coal
➕
Gold
➕
Platinum
➕
Battery Metals
➕
etc.
Receive all benefits from Option 1 or Option 2 delivered to numerous people at your company
➕
Multiple User names and Passwords for simultaneous log-ins
➕
Intranet integration access to all in your organisation